Tags

, , , , , , , , , ,

Below is the first part of an article by GlobalNewsWire on nasdaq.com. It reads…

NEW YORK, Dec. 16, 2013 (GLOBE NEWSWIRE) — Pomerantz Grossman Hufford Dahlstrom & Gross LLP has filed a class action lawsuit against Insys Therapeutics, Inc. (“Insys” or the “Company”) (Nasdaq:INSY) and certain of its officers. The class action, filed in United States District Court, District of Arizona, is on behalf of a class consisting of all persons or entities who purchased or otherwise acquired securities of Insys between May 1, 2013 and December 12, 2013 both dates inclusive (the “Class Period”). This class action seeks to recover damages against the Company and certain of its officers and directors as a result of alleged violations of the federal securities laws pursuant to Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder.

If you are a shareholder who purchased Insys securities during the Class Period, you have until February 14, 2014 to ask the Court to appoint you as Lead Plaintiff for the class. A copy of the Complaint can be obtained at www.pomerantzlaw.com. To discuss this action, contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888.476.6529 (or 888.4-POMLAW), toll free, x237. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and number of shares purchased.

Advertisements